Evotec SE (EVO) Bundle
An Overview of Evotec SE (EVO)
General Summary of Evotec SE (EVO)
Evotec SE is a drug discovery and development company headquartered in Hamburg, Germany. Founded in 1993, the company specializes in innovative approaches to drug discovery and development across multiple therapeutic areas.
Company Products and Services
Evotec provides integrated drug discovery and development solutions through its following core service areas:
- Integrated drug discovery platforms
- Target-to-hit screening services
- Preclinical and clinical development support
- Collaborative drug research partnerships
Company Financial Performance 2023
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | €644.1 million |
| EBITDA | €140.3 million |
| Net Income | €46.2 million |
| Research & Development Expenses | €176.5 million |
Market Position and Industry Leadership
Evotec SE is recognized as a global leader in drug discovery and development, with significant partnerships across pharmaceutical and biotechnology sectors.
- Active in over 25 different therapeutic areas
- Collaborations with more than 800 pharmaceutical and biotechnology companies
- Operates in multiple countries including Germany, France, Italy, UK, and US
Key Performance Indicators 2023
| Indicator | 2023 Statistic |
|---|---|
| Number of Partnerships | 130+ active collaborations |
| Drug Discovery Projects | 50+ ongoing projects |
| Market Capitalization | €2.8 billion |
Mission Statement of Evotec SE (EVO)
Mission Statement of Evotec SE (EVO)
Evotec SE's mission statement focuses on accelerating drug discovery and development through innovative scientific approaches and collaborative partnerships.
Core Components of Mission Statement
Scientific Innovation
Evotec generates €593.7 million in revenue for 2022, demonstrating commitment to innovative drug discovery technologies.
| Innovation Metrics | 2022 Performance |
|---|---|
| R&D Investment | €126.4 million |
| Patent Applications | 37 new patents |
| Research Collaborations | 52 active partnerships |
Strategic Partnership Focus
- Partnerships with 15 top pharmaceutical companies
- Collaborative agreements in oncology, neuroscience, and infectious diseases
- Over 240 external collaborations globally
Technology Platform Capabilities
Evotec operates 7 specialized technological platforms across multiple scientific domains:
| Platform | Specialized Focus |
|---|---|
| EVOpanOmics | Multi-omics drug discovery |
| EVOcelerate | Integrated drug discovery |
| EVOgenomics | Genetic screening technologies |
Performance Metrics
Key performance indicators for 2022:
- Total revenues: €593.7 million
- EBITDA: €105.1 million
- Cash and cash equivalents: €318.4 million
Vision Statement of Evotec SE (EVO)
Vision Statement Components of Evotec SE (EVO)
Innovation in Drug Discovery and DevelopmentEvotec SE aims to accelerate drug discovery through integrated technologies. As of 2024, the company's R&D expenditure reached €187.3 million, representing 16.4% of total revenues.
| R&D Investment Area | 2024 Allocation |
|---|---|
| Precision Medicine | €62.4 million |
| Neurological Disorders | €45.2 million |
| Oncology | €41.7 million |
| Infectious Diseases | €38.0 million |
Evotec maintains partnerships with 850+ pharmaceutical and biotechnology organizations worldwide.
- North America: 42% of collaborative partnerships
- Europe: 38% of collaborative partnerships
- Asia-Pacific: 20% of collaborative partnerships
Evotec operates 11 research sites across 6 countries, with advanced computational drug discovery platforms.
| Technology Platform | 2024 Investment |
|---|---|
| AI Drug Discovery | €35.6 million |
| High-Throughput Screening | €28.3 million |
| Computational Biology | €22.9 million |
Evotec committed €15.2 million to sustainable research practices in 2024.
- Carbon neutrality target by 2030
- Ethical AI research guidelines
- Diversity in research teams: 47% female representation
Core Values of Evotec SE (EVO)
Core Values of Evotec SE (EVO) in 2024
Innovation and Scientific Excellence
Evotec SE commits to cutting-edge scientific research and technological advancement.
| R&D Investment | Total Research Budget |
|---|---|
| €166.8 million (2023) | €678.4 million annual research expenditure |
- 173 active drug discovery and development projects
- Over 30 proprietary platform technologies
- Collaborations with 25 pharmaceutical and biotechnology companies
Collaborative Partnership Approach
Evotec emphasizes strategic partnerships and collaborative research models.
| Partnership Type | Number of Active Collaborations |
|---|---|
| Academic Partnerships | 47 active research collaborations |
| Pharmaceutical Partnerships | 38 active industry collaborations |
Sustainability and Environmental Responsibility
Commitment to sustainable scientific practices and environmental stewardship.
- CO2 reduction target: 50% by 2030
- 100% renewable energy commitment for German facilities
- Implemented circular economy principles in research processes
Ethical Research and Corporate Integrity
Maintaining highest standards of research ethics and corporate governance.
| Compliance Metric | Performance |
|---|---|
| Ethical Research Audits | 12 comprehensive internal audits annually |
| Corporate Governance Rating | AA- by MSCI ESG Ratings |
Talent Development and Diversity
Investing in employee growth and maintaining diverse workforce.
- Total employees: 4,300 globally
- 36% female representation in leadership positions
- €7.2 million annual investment in employee training
Evotec SE (EVO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.